PE20121159A1 - DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR - Google Patents

DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR

Info

Publication number
PE20121159A1
PE20121159A1 PE2011001861A PE2011001861A PE20121159A1 PE 20121159 A1 PE20121159 A1 PE 20121159A1 PE 2011001861 A PE2011001861 A PE 2011001861A PE 2011001861 A PE2011001861 A PE 2011001861A PE 20121159 A1 PE20121159 A1 PE 20121159A1
Authority
PE
Peru
Prior art keywords
amine
mtor
kinase
pyridin
methyl
Prior art date
Application number
PE2011001861A
Other languages
English (en)
Inventor
Kristin Andrews
Yuxin Y Bo
Shon Booker
Victor J Cee
Noel D'angelo
Bradley J Herberich
Fang-Tsao Hong
Claire L M Jackson
Brian A Lanman
Hongyu Liao
Longbin Liu
Nobuko Nishimura
Mark H Norman
Liping H Pettus
Anthony B Reed
Adrian L Smith
Seifu Tadesse
Nuria A Tamayo
Bin Wu
Ryan Wurz
Kevin Yang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20121159A1 publication Critical patent/PE20121159A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

REFERIDA A UN DERIVADO DE AMINA DE FORMULA (I), DONDE Ar1 ES UN ANILLO MONOCICLICO O BICICLICO DE 5 HASTA 10 MIEMBROS QUE PUEDE CONTENER DE 0 A 4 HETEROATOMOS SELECCIONADOS DE O, N Y S, EL CUAL PUEDE ESTAR SUSTITUIDO CON HALO, CN, NITRO, ENTRE OTROS; Q ES UN GRUPO (a); R2 ES METILO O ETILO; Z5 ES N O CRc; Z9 ES N, NR O CR; Z10 ES N, NR O CR; R ES H, OXO, HALOALQUILO C1-C4, ENTRE OTROS; Rc ES H, ALQUILO C1-C6, CF3, ENTRE OTROS; Z1, Z2, Z3 Y Z4 SON N, NR, CR, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(3-(4-AMINO-6-METIL-1,3,5-TRIZIN-2-IL)PIRIDIN-2-IL)-1H-INDOL-4-AMINA, 4-(2-(6-METOXIPIRIDIN-3-ILAMINO)PIRIDIN-3-IL)-6-METIL-1,3,5-TRIAZIN-2-AMINA, N-(3-(6-AMINO-2-METILPIRIMIDIN-4-IL)PIRIDIN-2-IL)-1H-INDAZOL-4-AMINA, ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA FOSFOINOSITIDA 3 CINASA (PIK3) Y/U OBJETIVO MAMIFERO DE RAPAMICINA (mTOR) Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2011001861A 2009-04-28 2010-04-27 DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR PE20121159A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17352009P 2009-04-28 2009-04-28
US25853209P 2009-11-05 2009-11-05

Publications (1)

Publication Number Publication Date
PE20121159A1 true PE20121159A1 (es) 2012-09-19

Family

ID=42315845

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001861A PE20121159A1 (es) 2009-04-28 2010-04-27 DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR

Country Status (24)

Country Link
US (2) US8362241B2 (es)
EP (1) EP2424859B1 (es)
JP (1) JP5697662B2 (es)
KR (1) KR20120007540A (es)
CN (1) CN102548984B (es)
AR (1) AR076486A1 (es)
AU (1) AU2010241723B2 (es)
BR (1) BRPI1015262A2 (es)
CA (1) CA2758986C (es)
CL (1) CL2011002691A1 (es)
CO (1) CO6440596A2 (es)
CR (1) CR20110634A (es)
EA (1) EA019700B1 (es)
HK (1) HK1167862A1 (es)
IL (1) IL215731A0 (es)
MA (1) MA34207B1 (es)
MX (1) MX2011011335A (es)
NZ (1) NZ595572A (es)
PE (1) PE20121159A1 (es)
SG (1) SG175364A1 (es)
TW (1) TW201103902A (es)
UY (1) UY32582A (es)
WO (1) WO2010126895A1 (es)
ZA (1) ZA201108101B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
WO2010108074A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Inhibitors of pi3 kinase
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
FR2958290B1 (fr) 2010-03-30 2012-10-19 Sanofi Aventis Procede de preparation de derives de sulfonamido-benzofurane
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
HUP1000330A2 (en) 2010-06-18 2011-12-28 Sanofi Sa Process for the preparation of dronedarone and the novel intermediates
CN103339132B (zh) * 2010-12-02 2017-02-15 株式会社麦迪帕克特 嘌呤基吡啶基氨基‑2,4‑二氟苯基磺酰胺衍生物、其药学上可接受的盐、其制备方法及包含其作为活性成分的对Raf激酶具有抑制活性的药物组合物
US9284270B2 (en) 2011-02-14 2016-03-15 The Governers Of The University Of Alberta Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids
AU2012225382B2 (en) * 2011-03-09 2016-10-27 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
HUP1100165A2 (en) 2011-03-29 2012-12-28 Sanofi Sa Process for preparation of dronedarone by n-butylation
HUP1100167A2 (en) 2011-03-29 2012-11-28 Sanofi Sa Process for preparation of dronedarone by mesylation
HUE059230T2 (hu) 2011-06-10 2022-10-28 Merck Patent Gmbh Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103102349B (zh) * 2011-11-14 2017-03-15 北京赛林泰医药技术有限公司 蛋白激酶抑制剂及其组合物和用途
KR101721739B1 (ko) * 2011-11-14 2017-03-30 치아타이 티안큉 파마수티컬 그룹 주식회사 키나제 조절 화합물, 이를 함유하는 조성물 및 그의 용도
FR2983198B1 (fr) 2011-11-29 2013-11-15 Sanofi Sa Procede de preparation de derives de 5-amino-benzoyl-benzofurane
EP2617718A1 (en) 2012-01-20 2013-07-24 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9221778B2 (en) 2012-02-13 2015-12-29 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
WO2013121234A1 (en) * 2012-02-14 2013-08-22 Sanofi Process for the preparation of dronedarone by oxidation of a sulphenyl group
US9382223B2 (en) 2012-02-22 2016-07-05 Sanofi Process for preparation of dronedarone by oxidation of a hydroxyl group
US9238636B2 (en) 2012-05-31 2016-01-19 Sanofi Process for preparation of dronedarone by Grignard reaction
CN104703985A (zh) * 2012-08-09 2015-06-10 神经孔疗法股份有限公司 作为pi3-激酶信号通路调节剂的芳基和杂芳基取代的苯衍生物
FR2994572B1 (fr) * 2012-08-17 2015-04-17 Centre Nat Rech Scient Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique
MX362896B (es) 2013-02-19 2019-02-22 Amgen Inc Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
WO2014177915A1 (en) 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
CN104513235B (zh) * 2013-09-02 2017-12-05 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
JP6340416B2 (ja) * 2013-09-25 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ホスファチジルイノシトール３−キナーゼ−ガンマの選択的インヒビター
EP4039256A1 (en) 2013-11-11 2022-08-10 Amgen Inc. Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
SI3157916T1 (sl) 2014-06-19 2019-05-31 Ariad Pharmaceuticals, Inc. Heteroarilne spojine za zaviranja kinaze
EP3351533A4 (en) 2015-09-18 2019-03-06 Kaken Pharmaceutical Co., Ltd. BIARY DERIVATIVE AND MEDICAMENT THEREOF
CN109071543B (zh) * 2016-02-03 2021-07-16 三进制药株式会社 抑制raf激酶和血管内皮生长因子受体的吡啶衍生物，其制备方法，含有其的药物组合物及其用途
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3526222B1 (en) * 2016-10-14 2022-08-17 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018089499A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
JP6469272B2 (ja) * 2017-03-01 2019-02-13 科研製薬株式会社 ビアリール誘導体又はその塩からなる医薬
CA3050359A1 (en) 2017-03-14 2018-09-20 Basf Se Herbicidal azines
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN111372579B (zh) 2017-10-30 2023-08-22 神经孔疗法股份有限公司 取代的苯基磺酰基苯基***硫酮和其用途
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7292394B2 (ja) * 2018-12-21 2023-06-16 サルティゴ・ゲーエムベーハー ２－アルコキシ－４－アミノ－５－メチル－ピリジン及び／又は２－アルコキシ－４－アルキルアミノ－５－メチル－ピリジンを調製するためのプロセス
WO2020146779A1 (en) * 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
EP4045047A1 (en) 2019-10-15 2022-08-24 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en) 2019-12-16 2023-01-26 Amgen Inc. Dosing regimen of kras g12c inhibitor
KR20230026384A (ko) * 2020-06-23 2023-02-24 선전 포워드 파머수티컬즈 코 엘티디 화합물의 결정 형태
CN116283467A (zh) * 2023-01-18 2023-06-23 四川大学 一种合成二芳基烷基甲烷的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
EP1242366A1 (en) 1999-12-15 2002-09-25 Axys Pharmaceuticals, Inc. Salicylamides as serine protease and factor xa inhibitors
IL151018A0 (en) 2000-03-17 2003-02-12 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
EA011402B1 (ru) 2004-01-23 2009-02-27 Эмджен Инк. Азотсодержащие гетероциклические производные и их фармацевтические применения
AU2005245386B2 (en) * 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
PT1864665E (pt) 2005-03-11 2012-06-27 Zenyaku Kogyo Kk Agente imunossupressor compreendendo um composto heterocíclico como ingrediente activo
EP2049497A2 (en) 2005-05-19 2009-04-22 Astex Therapeutics Limited Pyrimidine derivatives as hsp90 inhibitors
WO2007011721A1 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GEP20125643B (en) 2006-01-23 2012-09-25 Amgen Inc Aurora kinase modulators and method of using same
AU2007212345A1 (en) * 2006-02-06 2007-08-16 Irm Llc Compounds and compositions as protein kinase inhibitors
ES2365258T3 (es) * 2006-06-26 2011-09-27 Ucb Pharma S.A. Derivados de tiazol condensados como inhibidores de quinasa.
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090233926A1 (en) 2006-09-14 2009-09-17 Astrazeneca 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20100022534A1 (en) 2006-09-14 2010-01-28 Astrazeneca 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032086A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032041A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
EP2057147A1 (en) 2006-09-14 2009-05-13 Astra Zeneca AB Pyrimidine derivatives
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CA2675558A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
CN101801963A (zh) 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖性疾病的三取代的嘧啶衍生物
EA018708B1 (ru) 2007-07-09 2013-10-30 Астразенека Аб ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
AR067478A1 (es) 2007-07-09 2009-10-14 Astrazeneca Ab Compuestos derivados de morfolina pirimidina
ES2394126T3 (es) 2007-07-26 2013-01-22 Novartis Ag Derivados de pirimidina útiles para el tratamiento de estados inflamatorios o alérgicos
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2009093981A1 (en) 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
GEP20125589B (en) 2008-05-23 2012-07-25 Wyeth Llc TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
BRPI0911688A2 (pt) 2008-07-31 2015-07-28 Genentech Inc "compostos de pirimidina, composições e métodos de uso"
US20100113523A1 (en) 2008-10-30 2010-05-06 Alberte Randall S Tryptase Enzyme Inhibiting Aminopyridines
MX2011004570A (es) 2008-10-31 2011-06-17 Merck Sharp & Dohme Antagonistas del receptor p2x3 para el tratamiento del dolor.
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
TW201028399A (en) 2008-11-27 2010-08-01 Shionogi & Co Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
JP2012513410A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
WO2010093727A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
JP2012518037A (ja) 2009-02-18 2012-08-09 アムジエン・インコーポレーテツド ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物
EP2403847B1 (en) 2009-03-06 2016-03-02 UCB Biopharma SPRL Triazine derivatives as kinase inhibitors
NZ595372A (en) 2009-03-27 2013-11-29 Vetdc Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US20130023497A1 (en) 2009-06-08 2013-01-24 Chunlin Tao Triazine Derivatives and their Therapeutical Applications

Also Published As

Publication number Publication date
BRPI1015262A2 (pt) 2016-05-03
AU2010241723B2 (en) 2012-12-13
TW201103902A (en) 2011-02-01
US20100273764A1 (en) 2010-10-28
IL215731A0 (en) 2012-01-31
EP2424859A1 (en) 2012-03-07
CR20110634A (es) 2012-01-06
UY32582A (es) 2010-11-30
US8362241B2 (en) 2013-01-29
US8772480B2 (en) 2014-07-08
JP2012525395A (ja) 2012-10-22
ZA201108101B (en) 2012-07-25
SG175364A1 (en) 2011-11-28
EA201101583A1 (ru) 2012-05-30
CL2011002691A1 (es) 2012-03-16
CA2758986C (en) 2014-05-27
EA019700B1 (ru) 2014-05-30
WO2010126895A1 (en) 2010-11-04
AU2010241723A1 (en) 2011-11-17
HK1167862A1 (en) 2012-12-14
NZ595572A (en) 2013-07-26
KR20120007540A (ko) 2012-01-20
EP2424859B1 (en) 2015-04-08
MX2011011335A (es) 2011-11-18
US20130079303A1 (en) 2013-03-28
CO6440596A2 (es) 2012-05-15
MA34207B1 (fr) 2013-05-02
AR076486A1 (es) 2011-06-15
JP5697662B2 (ja) 2015-04-08
CN102548984A (zh) 2012-07-04
CN102548984B (zh) 2015-11-25
CA2758986A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
ES2509820T3 (es) Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
AR060401A1 (es) Derivados de cromen-2-ona
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
PE20121695A1 (es) 5-alquinil-pirimidinas
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
PE20090773A1 (es) Derivados de morfolina pirimidina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
MX353957B (es) Carboxamidas heterociclicas fungicidas.
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
WO2008152072A3 (de) Piperazinverbindungen mit herbizider wirkung
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR061603A1 (es) Derivados de etenilcarboxamidas microbicidas
AR056103A1 (es) Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20140609A1 (es) Diazacarbazoles y metodos de uso
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed